A novel approach to generate host antitumor T cells: Adoptive immunotherapy by T cells maturing in xenogeneic thymus

被引:0
作者
Zhao, Yong
Sun, Yimin
Niu, Zeqing
Li, Qinghuan
Peng, Jianxiao
Wang, Junjie
Langnas, Alan N.
机构
[1] Chinese Acad Sci, Inst Zool, Translat Biol Res Div, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100080, Peoples R China
[2] Peking Univ, Hosp 2, Dept Radiat Oncol, Beijing 100871, Peoples R China
[3] Univ Nebraska, Med Ctr, Dept Surg, Lied Transplant Ctr, Omaha, NE 68182 USA
关键词
transplantation; immune response; tumor immunity; adoptive immunotherapy; and melanoma;
D O I
10.1097/01.cji.0000211322.45772.d4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mouse or human T cells developing in xenogeneic porcine thymus are functional. With efficient peripheral repopulation of mouse T cells by grafting fetal pig thymus (FP THY), B6 nude mice were immunized with inactivated syngeneic melanoma, B16 cells. Splenocytes from B16-immunized FP THY-grafted B6 nude mice efficiently killed B16, but not EL4 target cells in cytotoxicity assays in vitro. Adoptive transfer of splenocytes from B16-immunizd FP THY-grafted B6 nude mice to B16-bearing B6 mice significantly prolonged recipient survival and inhibited B16 solid tumor growth when B16 cells were injected IV or SC, respectively, compared with the identical controls. Splenocytes from nonimmunized FP THY-grafted B6 nude mice failed to protect B6 mice from B16-induced mortality. The present data have demonstrated that mouse T cells maturing in xenogeneic thymus have the ability to kill syngeneic tumor cells. This study may offer a novel resource to produce host antitumor T cells for adoptive immunotherapy of tumor patients.
引用
收藏
页码:83 / 88
页数:6
相关论文
共 37 条
[1]   Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy [J].
AlexanderMiller, MA ;
Leggatt, GR ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4102-4107
[2]  
Boone CW, 1997, P SOC EXP BIOL MED, V216, P151
[3]  
Carrel Stefan, 1993, Current Opinion in Oncology, V5, P383, DOI 10.1097/00001622-199303000-00018
[4]   INDUCTION OF ANTITUMOR CYTOTOXIC T-LYMPHOCYTES IN NORMAL HUMANS USING PRIMARY CULTURES AND SYNTHETIC PEPTIDE EPITOPES [J].
CELIS, E ;
TSAI, V ;
CRIMI, C ;
DEMARS, R ;
WENTWORTH, PA ;
CHESNUT, RW ;
GREY, HM ;
SETTE, A ;
SERRA, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2105-2109
[5]   Therapy with cultured T cells: Principles revisited [J].
Cheever, MA ;
Chen, W .
IMMUNOLOGICAL REVIEWS, 1997, 157 :177-194
[6]  
Cohen PA, 2000, CRIT REV IMMUNOL, V20, P17
[7]   CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine [J].
Comes, A ;
Rosso, O ;
Orengo, AM ;
Di Carlo, E ;
Sorrentino, C ;
Meazza, R ;
Piazza, T ;
Valzasina, B ;
Nanni, P ;
Colombo, MP ;
Ferrini, S .
JOURNAL OF IMMUNOLOGY, 2006, 176 (03) :1750-1758
[8]   Recognition and lysis of human melanoma by a CD3(+), CD4(+), CD8(-) T-cell clone restricted by HLA-A2 [J].
Darrow, TL ;
AbdelWahab, Z ;
QuinnAllen, MA ;
Seigler, HF .
CELLULAR IMMUNOLOGY, 1996, 172 (01) :52-59
[9]   Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines [J].
Dolan, BP ;
Gibbs, KD ;
Ostrand-Rosenberg, S .
JOURNAL OF IMMUNOLOGY, 2006, 176 (03) :1447-1455
[10]   Self-recognition and tumor response to immunotherapy [J].
Ernstoff, MS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5875-5877